ACC: Semaglutide Beneficial in Patients With T2DM and Peripheral Artery Disease
Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes
ACC: Microplastic Exposure Tied to Chronic Disease Prevalence
Significant associations seen for high blood pressure, diabetes, and stroke
FDA Removes Top Expert on Vaping and Tobacco
FDA Approves Cabozantinib for Previously Treated Advanced Neuroendocrine Tumors
Patients treated with cabozantinib survived significantly longer with no worsening of their disease compared with patients who received placebo
Weight Loss Greater With Intermittent Fasting Than Calorie Restriction
Weight loss moderately greater with 4:3 IMF versus daily calorie restriction in adults with overweight, obesity
Low-Glucose Alerts Beneficial for Insulin-Treated Drivers With Diabetes
Low-glucose alerts improve time below range for drivers with T1D and reduce incidence of low glucose for all insulin-treated drivers
FDA Unveils Transparency Tool for Easy Check of Contaminant Levels in Foods
Tool is an online, searchable database that provides a consolidated list of contaminant levels
Water Aerobics Tied to Improvements in Body Weight for Overweight, Obesity
Findings based on data from 10 studies with 286 adults with overweight or obesity
Tirzepatide, Semaglutide Not Cost-Effective at Current Prices
Tirzepatide and semaglutide offer long-term health benefits, but would require discounts to reach $100,000/QALY threshold
Prevalence of Pediatric-Onset Chronic Conditions, Functional Limitations Increasing
Annual increase of 0.24 percentage points seen in children aged 5 to 17 years and of 0.33 percentage points for young adults age 18 to 25 years
